Symbols / BRTX $0.25 -9.71% BioRestorative Therapies, Inc.
BRTX Chart
About
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.40M |
| Enterprise Value | 4.19M | Income | -14.24M | Sales | 359.70K |
| Book/sh | 0.04 | Cash/sh | 0.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -0.48 | PEG | — |
| P/S | 17.78 | P/B | 6.44 | P/C | — |
| EV/EBITDA | -0.27 | EV/Sales | 11.64 | Quick Ratio | 0.80 |
| Current Ratio | 0.84 | Debt/Eq | 11.85 | LT Debt/Eq | — |
| EPS (ttm) | -1.58 | EPS next Y | -0.52 | EPS Growth | — |
| Revenue Growth | -54.70% | Earnings | 2026-03-26 16:00 | ROA | -119.56% |
| ROE | -3.20% | ROIC | — | Gross Margin | 93.37% |
| Oper. Margin | -195.17% | Profit Margin | 0.00% | Shs Outstand | 25.48M |
| Shs Float | 24.18M | Short Float | 6.48% | Short Ratio | 0.05 |
| Short Interest | — | 52W High | 2.04 | 52W Low | 0.19 |
| Beta | 0.27 | Avg Volume | 9.61M | Volume | 1.72M |
| Target Price | $8.00 | Recom | Strong_buy | Prev Close | $0.28 |
| Price | $0.25 | Change | -9.71% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-08-14 | main | Roth MKM | Buy → Buy | $18 |
| 2024-06-12 | main | Roth MKM | Buy → Buy | $15 |
| 2023-08-14 | reit | Roth MKM | Buy → Buy | $15 |
| 2022-12-07 | init | Roth Capital | — → Buy | $15 |
| 2022-09-28 | init | Maxim Group | — → Buy | $6 |
| 2021-12-01 | init | Roth Capital | — → Buy | $37 |
- BRTX Stock Price, Quote & Chart | BIORESTORATIVE THERAPIES INC (NASDAQ:BRTX) - ChartMill hu, 02 Apr 2026 07
- Back pain stem cell study to show blinded data from about 45 patients - Stock Titan hu, 19 Mar 2026 07
- Biorestorative Therapies, Inc. (BRTX) reports Q4 loss, lags revenue estimates - MSN Sun, 05 Apr 2026 14
- BIORESTORATIVE THERAPIES ($BRTX) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative hu, 26 Mar 2026 22
- BioRestorative Therapies, Inc.'s (NASDAQ:BRTX) Profit Outlook - simplywall.st Wed, 05 Nov 2025 08
- BRTX SEC Filings - Biorestorative Therapies Inc 10-K, 10-Q, 8-K Forms - Stock Titan Sat, 04 Apr 2026 00
- BioRestorative Therapies stock falls after $1.1M registered offering - Investing.com Mon, 06 Oct 2025 07
- BRTX Surges 11% on Earnings Beat—But Signs Point to a Bounce, Not a Breakout - Bitget Fri, 27 Mar 2026 07
- BioRestorative Therapies (BRTX) seeks 1.5B-share authorization ahead of May 26 vote - Stock Titan Fri, 03 Apr 2026 18
- Biorestorative Therapies, Inc. (BRTX) Announces Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget hu, 26 Mar 2026 07
- Back pain patients showed lasting gains in Phase 2 stem cell study - Stock Titan Mon, 30 Mar 2026 12
- Stem cell firm BioRestorative raises $5M for trials and R&D - Stock Titan Fri, 13 Feb 2026 08
- If You Invested $1,000 in Biorestorative Therapies Inc (BRTX) - Stock Titan Sun, 22 Mar 2026 14
- BioRestorative signs up 99 in chronic lumbar disc disease cell therapy trial - Stock Titan ue, 10 Feb 2026 08
- FDA meeting outlines expedited approval path for BioRestorative BRTX-100 - Stock Titan Wed, 11 Feb 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.36
-10.30%
|
0.40
+175.03%
|
0.15
+21.70%
|
0.12
|
| Operating Revenue |
|
0.36
-10.30%
|
0.40
+175.03%
|
0.15
+21.70%
|
0.12
|
| Cost Of Revenue |
|
0.02
-15.06%
|
0.03
|
0.00
|
—
|
| Reconciled Cost Of Revenue |
|
0.02
-15.06%
|
0.03
|
0.00
|
—
|
| Gross Profit |
|
0.34
-9.94%
|
0.37
+155.78%
|
0.15
|
—
|
| Operating Expense |
|
15.98
+33.99%
|
11.93
-21.95%
|
15.28
-19.49%
|
18.98
|
| Research And Development |
|
10.09
+50.51%
|
6.71
+66.24%
|
4.03
+14.84%
|
3.51
|
| Selling General And Administration |
|
5.89
+12.78%
|
5.22
-53.93%
|
11.33
-27.27%
|
15.58
|
| Selling And Marketing Expense |
|
—
|
—
|
—
|
—
|
| General And Administrative Expense |
|
5.89
+12.78%
|
5.22
-53.93%
|
11.33
-27.27%
|
15.58
|
| Other Gand A |
|
5.89
+12.78%
|
5.22
-53.93%
|
11.33
-27.27%
|
15.58
|
| Other Operating Expenses |
|
—
|
—
|
-0.08
+24.60%
|
-0.11
|
| Total Expenses |
|
16.01
+33.88%
|
11.96
-21.77%
|
15.28
-19.49%
|
18.98
|
| Operating Income |
|
-15.65
-35.41%
|
-11.56
+23.66%
|
-15.14
+19.75%
|
-18.86
|
| Total Operating Income As Reported |
|
-15.65
-35.41%
|
-11.56
+24.08%
|
-15.22
+19.78%
|
-18.97
|
| EBITDA |
|
-15.44
-35.82%
|
-11.37
+24.08%
|
-14.97
+20.12%
|
-18.74
|
| Normalized EBITDA |
|
-16.56
-25.68%
|
-13.18
+30.55%
|
-18.97
+21.83%
|
-24.27
|
| Reconciled Depreciation |
|
0.21
+11.07%
|
0.19
+14.07%
|
0.17
+37.49%
|
0.12
|
| EBIT |
|
-15.65
-35.41%
|
-11.56
+23.66%
|
-15.14
+19.75%
|
-18.86
|
| Total Unusual Items |
|
1.12
-38.00%
|
1.81
-54.75%
|
4.00
-27.61%
|
5.52
|
| Total Unusual Items Excluding Goodwill |
|
1.12
-38.00%
|
1.81
-54.75%
|
4.00
-27.61%
|
5.52
|
| Special Income Charges |
|
—
|
—
|
0.00
-100.00%
|
0.25
|
| Other Special Charges |
|
—
|
—
|
—
|
-0.25
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-14.24
-58.61%
|
-8.98
+13.81%
|
-10.42
+21.21%
|
-13.22
|
| Pretax Income |
|
-14.24
-58.61%
|
-8.98
+13.81%
|
-10.42
+21.21%
|
-13.22
|
| Net Non Operating Interest Income Expense |
|
0.27
-56.79%
|
0.62
+11.55%
|
0.55
+4640.71%
|
0.01
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
—
|
| Net Interest Income |
|
0.27
-56.79%
|
0.62
+11.55%
|
0.55
+4640.71%
|
0.01
|
| Interest Expense |
|
—
|
—
|
—
|
—
|
| Interest Income Non Operating |
|
0.27
-56.79%
|
0.62
+11.55%
|
0.55
+4640.71%
|
0.01
|
| Interest Income |
|
0.27
-56.79%
|
0.62
+11.55%
|
0.55
+4640.71%
|
0.01
|
| Other Income Expense |
|
1.14
-41.88%
|
1.96
-52.98%
|
4.17
-25.97%
|
5.63
|
| Other Non Operating Income Expenses |
|
0.02
-88.43%
|
0.15
-11.09%
|
0.17
+58.43%
|
0.11
|
| Gain On Sale Of Security |
|
1.12
-38.00%
|
1.81
-54.75%
|
4.00
-24.18%
|
5.27
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-14.24
-58.61%
|
-8.98
+13.81%
|
-10.42
+21.21%
|
-13.22
|
| Net Income From Continuing Operation Net Minority Interest |
|
-14.24
-58.61%
|
-8.98
+13.81%
|
-10.42
+21.21%
|
-13.22
|
| Net Income From Continuing And Discontinued Operation |
|
-14.24
-58.61%
|
-8.98
+13.81%
|
-10.42
+21.21%
|
-13.22
|
| Net Income Continuous Operations |
|
-14.24
-58.61%
|
-8.98
+13.81%
|
-10.42
+21.21%
|
-13.22
|
| Normalized Income |
|
-15.36
-42.41%
|
-10.79
+25.16%
|
-14.42
+23.10%
|
-18.74
|
| Net Income Common Stockholders |
|
-14.24
-58.61%
|
-8.98
+13.81%
|
-10.42
+21.21%
|
-13.22
|
| Diluted EPS |
|
-1.58
-36.21%
|
-1.16
+53.04%
|
-2.47
+32.33%
|
-3.65
|
| Basic EPS |
|
-1.58
-36.21%
|
-1.16
+53.04%
|
-2.47
+32.33%
|
-3.65
|
| Basic Average Shares |
|
8.99
+15.83%
|
7.76
+84.05%
|
4.22
+16.60%
|
3.62
|
| Diluted Average Shares |
|
8.99
+15.83%
|
7.76
+84.05%
|
4.22
+16.60%
|
3.62
|
| Diluted NI Availto Com Stockholders |
|
-14.24
-58.61%
|
-8.98
+13.81%
|
-10.42
+21.21%
|
-13.22
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
-0.01
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
4.08
-66.78%
|
12.28
-2.63%
|
12.61
-23.26%
|
16.43
|
| Current Assets |
|
3.14
-71.85%
|
11.14
-2.16%
|
11.39
-24.71%
|
15.13
|
| Cash Cash Equivalents And Short Term Investments |
|
2.95
-72.49%
|
10.73
-3.01%
|
11.07
-24.97%
|
14.75
|
| Cash And Cash Equivalents |
|
1.51
+175.82%
|
0.55
-38.05%
|
0.88
-48.40%
|
1.71
|
| Cash Financial |
|
—
|
—
|
—
|
—
|
| Other Short Term Investments |
|
1.44
-85.84%
|
10.18
+0.03%
|
10.18
-21.89%
|
13.04
|
| Receivables |
|
0.02
-91.77%
|
0.19
+876.17%
|
0.02
+20.63%
|
0.02
|
| Accounts Receivable |
|
0.02
-91.77%
|
0.19
+876.17%
|
0.02
+20.63%
|
0.02
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
0.17
-24.54%
|
0.22
-26.87%
|
0.31
-15.93%
|
0.36
|
| Total Non Current Assets |
|
0.94
-16.98%
|
1.14
-7.01%
|
1.22
-6.51%
|
1.31
|
| Net PPE |
|
0.36
-1.15%
|
0.36
-28.49%
|
0.51
+0.94%
|
0.50
|
| Gross PPE |
|
1.59
+7.87%
|
1.47
-2.98%
|
1.52
+5.61%
|
1.44
|
| Accumulated Depreciation |
|
-1.23
-10.82%
|
-1.11
-9.81%
|
-1.01
-8.12%
|
-0.94
|
| Buildings And Improvements |
|
—
|
—
|
0.15
-37.36%
|
0.24
|
| Machinery Furniture Equipment |
|
0.28
+0.00%
|
0.28
+0.00%
|
0.28
+7.18%
|
0.26
|
| Construction In Progress |
|
0.06
|
0.00
|
—
|
—
|
| Other Properties |
|
0.91
+6.09%
|
0.85
-5.04%
|
0.90
+51.06%
|
0.59
|
| Leases |
|
0.34
+0.00%
|
0.34
+0.00%
|
0.34
+0.00%
|
0.34
|
| Goodwill And Other Intangible Assets |
|
0.53
-14.38%
|
0.62
-12.58%
|
0.71
-11.17%
|
0.80
|
| Other Intangible Assets |
|
0.53
-14.38%
|
0.62
-12.58%
|
0.71
-11.17%
|
0.80
|
| Non Current Deferred Assets |
|
0.05
-66.50%
|
0.15
|
0.00
|
—
|
| Total Liabilities Net Minority Interest |
|
3.72
-0.68%
|
3.75
+43.76%
|
2.61
-57.57%
|
6.14
|
| Current Liabilities |
|
3.72
-0.68%
|
3.75
+43.76%
|
2.61
-56.41%
|
5.98
|
| Payables And Accrued Expenses |
|
1.61
+207.52%
|
0.52
-41.90%
|
0.90
+199.39%
|
0.30
|
| Payables |
|
1.48
+191.92%
|
0.51
+168.52%
|
0.19
+10.82%
|
0.17
|
| Accounts Payable |
|
1.34
+177.70%
|
0.48
+155.07%
|
0.19
+10.82%
|
0.17
|
| Other Payable |
|
0.14
+461.40%
|
0.03
|
—
|
—
|
| Current Accrued Expenses |
|
0.13
+736.49%
|
0.01
-97.89%
|
0.71
+447.15%
|
0.13
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.71
+1.35%
|
0.70
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
0.16
+16.50%
|
0.14
|
| Current Debt |
|
—
|
—
|
—
|
—
|
| Other Current Borrowings |
|
—
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.16
+16.50%
|
0.14
|
| Other Current Liabilities |
|
1.40
-44.49%
|
2.52
+63.27%
|
1.54
-72.14%
|
5.54
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.16
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
0.16
|
| Long Term Debt |
|
—
|
—
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.16
|
| Stockholders Equity |
|
0.36
-95.82%
|
8.53
-14.72%
|
10.00
-2.78%
|
10.29
|
| Common Stock Equity |
|
0.34
-95.98%
|
8.52
-14.74%
|
9.99
-2.77%
|
10.28
|
| Capital Stock |
|
0.01
+1.33%
|
0.01
+1.53%
|
0.01
-7.06%
|
0.02
|
| Common Stock |
|
0.00
+28.18%
|
0.00
+46.92%
|
0.00
+27.64%
|
0.00
|
| Preferred Stock |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
-7.90%
|
0.02
|
| Share Issued |
|
8.88
+28.27%
|
6.92
+47.02%
|
4.71
+27.98%
|
3.68
|
| Ordinary Shares Number |
|
8.88
+28.27%
|
6.92
+47.02%
|
4.71
+27.98%
|
3.68
|
| Additional Paid In Capital |
|
170.26
+3.70%
|
164.20
+4.79%
|
156.69
+6.91%
|
146.56
|
| Retained Earnings |
|
-169.92
-9.15%
|
-155.68
-6.12%
|
-146.70
-7.64%
|
-136.28
|
| Total Equity Gross Minority Interest |
|
0.36
-95.82%
|
8.53
-14.72%
|
10.00
-2.78%
|
10.29
|
| Total Capitalization |
|
0.36
-95.82%
|
8.53
-14.72%
|
10.00
-2.78%
|
10.29
|
| Working Capital |
|
-0.59
-107.92%
|
7.40
-15.80%
|
8.78
-3.97%
|
9.15
|
| Invested Capital |
|
0.34
-95.98%
|
8.52
-14.74%
|
9.99
-2.77%
|
10.28
|
| Total Debt |
|
—
|
0.00
-100.00%
|
0.16
-46.19%
|
0.30
|
| Capital Lease Obligations |
|
—
|
0.00
-100.00%
|
0.16
-46.19%
|
0.30
|
| Net Tangible Assets |
|
-0.18
-102.24%
|
7.91
-14.89%
|
9.29
-2.07%
|
9.49
|
| Tangible Book Value |
|
-0.19
-102.43%
|
7.89
-14.91%
|
9.28
-2.06%
|
9.47
|
| Preferred Shares Number |
|
1.40
-9.40%
|
1.54
+10.37%
|
1.40
-7.90%
|
1.52
|
| Preferred Stock Equity |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
-7.90%
|
0.02
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-10.79
-31.09%
|
-8.23
-27.99%
|
-6.43
-8.75%
|
-5.91
|
| Cash Flow From Continuing Operating Activities |
|
-10.79
-31.09%
|
-8.23
-27.99%
|
-6.43
-8.75%
|
-5.91
|
| Net Income From Continuing Operations |
|
-14.24
-58.61%
|
-8.98
+13.81%
|
-10.42
+21.21%
|
-13.22
|
| Depreciation Amortization Depletion |
|
0.21
+11.07%
|
0.19
+14.07%
|
0.17
+37.49%
|
0.12
|
| Depreciation |
|
0.12
+21.07%
|
0.10
+30.69%
|
0.08
+80.02%
|
0.04
|
| Amortization Cash Flow |
|
0.09
+0.00%
|
0.09
+0.00%
|
0.09
+14.57%
|
0.08
|
| Depreciation And Amortization |
|
0.21
+11.07%
|
0.19
+14.07%
|
0.17
+37.49%
|
0.12
|
| Amortization Of Intangibles |
|
0.09
+0.00%
|
0.09
+0.00%
|
0.09
+14.57%
|
0.08
|
| Other Non Cash Items |
|
—
|
0.15
+67.69%
|
0.09
+200.48%
|
-0.09
|
| Stock Based Compensation |
|
3.33
+18.24%
|
2.81
-63.86%
|
7.78
-38.29%
|
12.61
|
| Operating Gains Losses |
|
-1.39
+42.78%
|
-2.43
+46.73%
|
-4.57
+14.61%
|
-5.35
|
| Gain Loss On Investment Securities |
|
-1.39
+42.78%
|
-2.43
+46.73%
|
-4.57
+14.61%
|
-5.35
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
—
|
—
|
-0.03
|
| Change In Working Capital |
|
1.31
+4470.12%
|
0.03
-94.44%
|
0.52
+3543.42%
|
0.01
|
| Change In Receivables |
|
0.17
+202.25%
|
-0.17
-5024.24%
|
-0.00
+70.00%
|
-0.01
|
| Changes In Account Receivables |
|
0.17
+202.25%
|
-0.17
-5024.24%
|
-0.00
+70.00%
|
-0.01
|
| Change In Prepaid Assets |
|
0.10
+202.97%
|
0.03
-41.94%
|
0.06
-20.86%
|
0.07
|
| Change In Payables And Accrued Expense |
|
1.03
+216.96%
|
0.33
-45.60%
|
0.60
+421.03%
|
0.12
|
| Change In Accrued Expense |
|
0.20
+495.39%
|
0.03
-94.36%
|
0.58
+11974.56%
|
-0.00
|
| Change In Payable |
|
0.84
+185.86%
|
0.29
+1488.58%
|
0.02
-84.60%
|
0.12
|
| Change In Account Payable |
|
0.84
+185.86%
|
0.29
+1488.58%
|
0.02
-84.60%
|
0.12
|
| Change In Other Current Liabilities |
|
0.00
+100.00%
|
-0.16
-16.50%
|
-0.14
+14.59%
|
-0.16
|
| Investing Cash Flow |
|
8.90
+1629.25%
|
0.51
-84.18%
|
3.25
+124.27%
|
-13.40
|
| Cash Flow From Continuing Investing Activities |
|
8.90
+1629.25%
|
0.51
-84.18%
|
3.25
+124.27%
|
-13.40
|
| Net PPE Purchase And Sale |
|
-0.12
-9.30%
|
-0.11
+37.92%
|
-0.17
+35.51%
|
-0.27
|
| Purchase Of PPE |
|
-0.12
-9.30%
|
-0.11
+37.92%
|
-0.17
+35.51%
|
-0.27
|
| Capital Expenditure |
|
-0.12
-9.30%
|
-0.11
+37.92%
|
-0.17
+61.15%
|
-0.44
|
| Net Investment Purchase And Sale |
|
9.01
+1352.11%
|
0.62
-81.87%
|
3.42
+126.41%
|
-12.96
|
| Purchase Of Investment |
|
-2.68
+87.17%
|
-20.89
-19.08%
|
-17.54
+21.87%
|
-22.45
|
| Sale Of Investment |
|
11.69
-45.64%
|
21.51
+2.60%
|
20.96
+120.86%
|
9.49
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
0.00
+100.00%
|
-0.17
|
| Purchase Of Intangibles |
|
—
|
—
|
0.00
+100.00%
|
-0.17
|
| Financing Cash Flow |
|
2.85
-61.31%
|
7.38
+214.18%
|
2.35
|
0.00
|
| Cash Flow From Continuing Financing Activities |
|
2.85
-61.31%
|
7.38
+214.18%
|
2.35
|
0.00
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
3.10
|
0.00
-100.00%
|
2.35
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.04
-99.45%
|
7.53
|
0.00
|
—
|
| Net Other Financing Charges |
|
-0.28
-90.07%
|
-0.15
|
—
|
—
|
| Changes In Cash |
|
0.96
+386.28%
|
-0.34
+59.43%
|
-0.83
+95.71%
|
-19.31
|
| Beginning Cash Position |
|
0.55
-38.05%
|
0.88
-48.40%
|
1.71
-91.85%
|
21.03
|
| End Cash Position |
|
1.51
+175.82%
|
0.55
-38.05%
|
0.88
-48.40%
|
1.71
|
| Free Cash Flow |
|
-10.91
-30.81%
|
-8.34
-26.29%
|
-6.60
-3.90%
|
-6.35
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Change In Interest Payable |
|
—
|
—
|
—
|
—
|
| Common Stock Issuance |
|
3.10
|
0.00
-100.00%
|
2.35
|
0.00
|
| Issuance Of Capital Stock |
|
3.10
|
0.00
-100.00%
|
2.35
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-26 View
- 8-K2026-02-17 View
- 10-Q2025-11-12 View
- 8-K2025-11-12 View
- 42025-10-20 View
- 42025-10-20 View
- 8-K2025-10-08 View
- 8-K2025-09-25 View
- 8-K2025-08-14 View
- 10-Q2025-08-12 View
- 8-K2025-08-12 View
- 8-K2025-06-13 View
- 10-Q2025-05-14 View
- 8-K2025-05-14 View
- 8-K2025-04-21 View
- 10-K2025-03-28 View
- 8-K2025-03-27 View
- 42025-02-19 View
- 42025-02-19 View
- 42025-02-19 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|